Remant Bahadur K C, Chandrashekaran Varun, Cheng Bei, Chen Hexin, Peña Maria Marjorette O, Zhang Jiajia, Montgomery Janis, Xu Peisheng
Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina , 715 Sumter Street, Columbia, South Carolina 29208, United States.
Mol Pharm. 2014 Jun 2;11(6):1897-905. doi: 10.1021/mp5000482. Epub 2014 May 9.
Ideal "smart" nanoparticles for drug delivery should enhance therapeutic efficacy without introducing side effects. To achieve that, we developed a drug delivery system (HCN) based on a polymer-drug conjugate of poly[2-(pyridin-2-yldisulfanyl)]-graft-poly(ethylene glycol) and camptothecin with an intracellularly cleavable linker and human epidermal growth factor receptor 2 (HER2) targeting ligands. An in vitro drug release study found that HCN was stable in the physiological environment and supersensitive to the stimulus of elevated intracellular redox potential, releasing all payloads in less than 30 min. Furthermore, confocal microscopy revealed that HCN could specifically enter HER2-positive cancer cells. As a consequence, HCN could effectively kill HER2-positive cancer cells while not affecting HER2-negative cells.
理想的用于药物递送的“智能”纳米颗粒应在不产生副作用的情况下提高治疗效果。为实现这一目标,我们开发了一种药物递送系统(HCN),它基于聚[2-(吡啶-2-基二硫烷基)]-接枝-聚乙二醇与喜树碱的聚合物-药物共轭物,带有细胞内可裂解的连接子和人表皮生长因子受体2(HER2)靶向配体。一项体外药物释放研究发现,HCN在生理环境中稳定,对细胞内氧化还原电位升高的刺激超敏感,能在不到30分钟内释放所有有效载荷。此外,共聚焦显微镜显示HCN可特异性进入HER2阳性癌细胞。因此,HCN可有效杀死HER2阳性癌细胞,同时不影响HER2阴性细胞。